Elacestrant is in clinical development for the treatment of oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-negative), advanced or metastatic breast cancer in patients who have progressed after prior treatment. Breast cancer is when abnormal cells in the breast begin to grow and divide in an uncontrolled way and eventually form a growth (tumour). Cancers that have receptors for the hormone oestrogen are ER+, and HER2-negative means that the cancerous cells do not contain high levels of the protein HER2. Metastatic cancers have spread from where they started to other parts of the body. There is a major unmet need for breast cancer patients who have progressed after receiving standard endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
Elacestrant for treating HER2-negative, ER-positive, advanced breast cancer after endocrine therapy
Elacestrant is in clinical development for the treatment of oestrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-negative), advanced or metastatic breast cancer in patients who have progressed after prior treatment. Breast cancer is when abnormal cells in the breast begin to grow and divide in an uncontrolled way and eventually form a growth (tumour).